Nymox Pharmaceutical Company Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe.

Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma.

The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure.

In addition, it develops drugs for the treatment of Alzheimer’s disease. The company was founded in 1989 and is headquartered in Nassau, Bahamas.

Nymox Pharmaceutical Corporation

Country	Bahamas
Founded	1989
Industry	Biotechnology
Sector	Healthcare
Employees	16
CEO	Paul Averback

Contact Details

Address: Bay & Deveaux Streets Nassau Bahamas
Phone	800 936 9669
Website	nymox.com

Stock Details

Ticker Symbol	NYMXF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	BSP733981026
SIC Code	2835

Key Executives

Name	Position
Dr. Paul Averback DABP, M.D.	Founder, Chairman, Chief Executive Officer and President
Lin Dodd	QA and Compliance Manager
Patrick Doody	Vice President, General Counsel and Director